Journal: Journal of abnormal psychology

Article Title: Blunted Neural Response to Rewards as a Vulnerability Factor for Depression: Results from a Family Study

doi: 10.1037/abn0000081

Figure Lengend Snippet: Scatterplots depicting the association between proband PA and sibling Event-Related Potential (ERP) to rewards. The zero-order correlation is depicted on the left. The right panel depicts the association controlling for the familial nature of the neural response to rewards, proband NA, and sibling PA and NA.

Article Snippet: Using the Matlab ERP PCA Toolbox - Version 2 ( Dien, 2010a ), a temporal PCA was performed first in order to capture variance across time and to maximize the initial separation of ERP components ( Dien & Frishkoff, 2005 ).

Techniques:

Journal: Journal of abnormal psychology

Article Title: Blunted Neural Response to Rewards as a Vulnerability Factor for Depression: Results from a Family Study

doi: 10.1037/abn0000081

Figure Lengend Snippet: Stimulus-locked Event-Related Potential (ERP) waveforms at electrode site FCz for siblings. For presentation purposes, a median split was conducted on proband PA to create groups of siblings of probands who were high in PA and siblings of probands who were low in PA. Responses to non-reward in siblings of high and low PA probands are on the left, corresponding responses to reward are on the right. For each panel, feedback onset occurred at 0 ms. Per ERP convention, negative voltages are plotted up.

Article Snippet: Using the Matlab ERP PCA Toolbox - Version 2 ( Dien, 2010a ), a temporal PCA was performed first in order to capture variance across time and to maximize the initial separation of ERP components ( Dien & Frishkoff, 2005 ).

Techniques:

Journal: Pharmaceutics

Article Title: Beyond Formulation: Contributions of Nanotechnology for Translation of Anticancer Natural Products into New Drugs

doi: 10.3390/pharmaceutics14081722

Figure Lengend Snippet: Main characteristics of doxorubicin (DOX) and paclitaxel (PTX) formulations, such as their administration route, therapeutic applications, recommended dose, and maximum tolerated dose (MTD). (* indicates cumulative dose) (NSCLC—non-small cell lung cancer).

Article Snippet: As Doxil ® patent expired in 2010, a generic version called Lipodox ® was developed by Sun Pharmaceutical Industries Ltd. (Mumbai, India) and approved by the USFDA in 2013.

Techniques: Formulation

Journal: Pharmaceutics

Article Title: Beyond Formulation: Contributions of Nanotechnology for Translation of Anticancer Natural Products into New Drugs

doi: 10.3390/pharmaceutics14081722

Figure Lengend Snippet: Proposed mechanisms for Doxil ® and Abraxane ® tumor accumulation. After being injected intravenously, the pegylated liposomes of doxorubicin (DOX—orange) formulation may reach the tumor through passive targeting/enhanced permeation-retention (EPR) effect (1), since this site presents irregular vascular architecture with fenestrated capillaries and impaired lymphatic drainage. The presence of polyethylene glycol (PEG) in Doxil ® corona provides a hydration layer that repels opsonins from the liposome and avoids phagocytosis by cells of the reticuloendothelial system (RES), such as macrophages (2). DOX may be released through three distinct mechanisms: secretion of phospholipases (3) or ammonia (4) by tumor cells or endocytosis followed by lysosomal processing (5). Abraxane ® presents other peculiarities: it probably dissociates into smaller complexes composed of albumin and paclitaxel (PTX; blue) (6). These structures, such as Doxil ® , may accumulate in tumor microenvironment, by EPR effect (1), transcytosis through binding receptors (glycoprotein 60—gp60) in endothelial cells (7), and interaction with secreted protein acidic and rich in cysteine (SPARC—yellow) (8). Albumin may be endocytosed through the caveolin-1 pathway (9), followed by lysosomal processing with subsequent drug release (5). (Created with BioRender.com ).

Article Snippet: As Doxil ® patent expired in 2010, a generic version called Lipodox ® was developed by Sun Pharmaceutical Industries Ltd. (Mumbai, India) and approved by the USFDA in 2013.

Techniques: Injection, Liposomes, Formulation, Binding Assay